

ONLINE SUPPLEMENT

Prothrombotic factors do not increase the risk of recurrent ischemic events after cryptogenic stroke at young age The FUTURE Study

M.M.I. Schellekens* MD; M.E. van Alebeek* MD; R.M. Arntz* MD, PhD; N.E. Synhaeve†, MD, PhD; N.A.M.M. Maaijwee‡, MD, PhD; H. Schoonderwaldt MD, PhD, M.J. van der Vlugt§ MD, PhD; E.J. van Dijk* MD, PhD; L.C.A. Rutten-Jacobs¶, PhD; F.H. de Leeuw* MD, PhD

Corresponding author: Professor Frank-Erik de Leeuw

RadboudUMC, department of Neurology, PO Box 9101, 6500 HB Nijmegen, the Netherlands

T: +3124-3616600 F: +3124-3618837

FrankErik.deLeeuw@radboudumc.nl

* Radboudumc, Donders Institute for Brain, Cognition and Behaviour, Center for Neuroscience, department of Neurology, PO Box 9101, 6500 HB Nijmegen, the Netherlands

† Department of Neurology, Elisabeth Tweesteden Hospital, PO Box 90151, 5000, LC Tilburg, the Netherlands

‡ Center for Neurology and Neurorehabilitation, Luzern State Hospital, Spitalstrasse 31, 6000, Luzern 16, Switzerland.

§ Radboudumc, department of Cardiology, PO Box 9101, 6500, HB Nijmegen, the Netherlands

¶ University of Cambridge, Department of Clinical Neurosciences, Cambridge, United Kingdom

Supplemental Table

Supplementary Table I Distribution of prothrombotic factors and recent infections stratified by TOAST category.

	Positive result/n _{investigated} (%)							
	Total	Large artery disease	Likely large artery disease	Cardio-embolic stroke	Small vessel disease	Other defined	Multiple causes	Unknown
Prothrombotic factors								
Protein C activity	7/255 (2.7)	1/10 (10.0)	0/41 (0)	1/25 (4.0)	1/32 (3.1)	1/39 (2.6)	1/8 (12.5)	2/100 (2.0)
Free protein S antigen	6/252 (2.4)	0/10 (0)	1/41 (2.4)	0/26 (0)	0/32 (0)	1/37 (2.7)	1/7 (14.3)	3/99 (3.0)
Antithrombin III activity	15/262 (5.7)	1/10 (10.0)	3/42 (7.1)	2/34 (5.9)	2/32 (6.3)	4/37 (10.8)	0/8 (0)	3/99 (3.0)
Factor V mutation	10/207 (4.8)	0/7 (0)	0/30 (0)	0/28 (0)	2/29 (6.9)	6/34 (17.6)	0/3 (0)	2/76 (2.6)
Factor II mutation	3/189 (1.6)	0/6 (0)	0/29 (0)	1/27 (3.7)	1/24 (4.2)	0/29 (0)	0/3 (0)	1/71 (1.4)
Factor VIII activity	10/157 (6.4)	0/4 (0)	1/29 (3.4)	2/23 (8.7)	3/19 (15.8)	1/26 (3.8)	0/4 (0)	3/52 (5.8)
Lupus anticoagulant	7/262 (2.7)	0/10 (0)	1/40 (2.5)	1/32 (3.1)	0/32 (0)	3/39 (7.7)	1/9 (11.1)	1/100 (1.0)
Anticardiolipin IgG	6/249 (2.4)	0/10 (0)	1/36 (2.8)	0/34 (0)	1/30 (3.3)	0/39 (0)	1/6 (16.7)	3/94 (3.2)
Anticardiolipin IgM	7/248 (2.8)	0/10 (0)	1/36 (2.8)	1/34 (2.9)	0/30 (0)	0/39 (0)	1/6 (16.7)	4/93 (4.3)
Any prothrombotic factor	56/294 (19.0)	1/10 (10.0)	6/45 (13.3)	7/40 (17.5)	8/35 (22.9)	14/46 (30.4)	3/9 (33.3)	17/109 (15.6)
Any aPL	17/284 (6.0)	0/10 (0)	3/40 (7.0)	2/37 (5.4)	1/34 (2.9)	3/44 (6.8)	2/9 (22.2)	6/107 (5.6)
Infectious pathogens								
Borrelia IgG	3/239 (1.3)	0/12 (0)	1/36 (2.8)	0/28 (0)	1/30 (3.3)	0/42 (0)	0/4 (0)	1/87 (1.1)
Borrelia IgM	5/239 (2.1)	0/12 (0)	1/36 (2.8)	0/28 (0)	1/30 (3.3)	1/42 (2.4)	0/4 (0)	2/87 (2.3)
Syphilis	1/249 (0.4)	0/13 (0)	0/38 (0)	0/30 (0)	0/30 (0)	0/41 (0)	0/6 (0)	1/91 (1.1)

Abbreviations: TOAST, Trial of ORG 10172 in Acute Stroke Treatment; aPL, antiphospholipid antibody.